[
    "{\"step_by_step_thinking\": \"Based on the information provided, the phase 3 clinical trial (MINDSET) of Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease did not show statistically significant differences between the Intepirdine and placebo groups on the co-primary endpoints of cognition and activities of daily living. Additionally, another phase 2b clinical trial (HEADWAY-DLB) of Intepirdine in patients with dementia with Lewy bodies also did not demonstrate significant benefits over placebo. Furthermore, the document mentions that Axovant Sciences, the company that acquired the rights to Intepirdine, discontinued the development of this drug. Therefore, based on the available evidence, the answer is B. no, Intepirdine should not be used for Alzheimer's disease.\", \"answer_choice\": \"B\"}"
]